Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최한곤 | - |
dc.date.accessioned | 2018-03-22T01:33:20Z | - |
dc.date.available | 2018-03-22T01:33:20Z | - |
dc.date.issued | 2016-03 | - |
dc.identifier.citation | BIOMEDICINE & PHARMACOTHERAPY, v. 78, Page. 226-233 | en_US |
dc.identifier.issn | 0753-3322 | - |
dc.identifier.issn | 1950-6007 | - |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0753332215302389 | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/50258 | - |
dc.description.abstract | Pulmonary fibrosis is a chronic lung disease characterized by inflammation and collagen deposition, with an estimated mortality rate exceeding 70%. Here, we evaluated the therapeutic effectiveness of inhaled tacrolimus-loaded chitosan-coated poly(lactic-co-glycolic acid) nanoparticles (chitosan TAC PLGA-NPs) in a bleomycin-induced pulmonary fibrosis mouse model. Chitosan TAC PLGA-NPs were fabricated using an o/w emulsification diffusion method, and uncoated TAC PLGA-NPs and chitosan TAC PLGA-NPs were spherical with approximate diameters of 320 and 441 nm, respectively. The zeta potential of chitosan TAC PLGA-NPs (+ 13.6 mV) was increased significantly by chitosan-coating versus uncoated TAC PLGA-NPs (similar to 28.3 mV). The incorporation efficiency of tacrolimus was 37.7%, and the tacrolimus was gradually released until about 5 day. Direct inhalation of chitosan TAC PLGA-NPs (TAC 180 mg/mouse) twice a week produced marked anti-fibrotic efficacy in mice with bleomycin-induced pulmonary fibrosis, which was much better than the efficacy resulting from daily oral administration (TAC 300 mg/mouse) on the basis of hematoxylin/eosin and Masson's trichrome staining assessments. Imaging of lung deposition showed that chitosan TAC PLGA-NPs were located well in the lungs and gradually faded over 96 h. The pulmonary delivery of tacrolimus could be therapeutically efficacious for treating pulmonary fibrosis. TAC-loaded PLGA nanoparticles should be considered to be an efficient sustained-release type inhalation system that reduces administration frequency and relevant side effects. (C) 2016 Elsevier Masson SAS. All rights reserved. | en_US |
dc.description.sponsorship | This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT, and Future Planning (#2014002133). | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER | en_US |
dc.subject | Tacrolimus | en_US |
dc.subject | PLGA nanoparticle | en_US |
dc.subject | Chitosan | en_US |
dc.subject | Pulmonary fibrosis | en_US |
dc.subject | Inhalation | en_US |
dc.title | Treatment of bleomycin-induced pulmonary fibrosis by inhaled tacrolimus-loaded chitosan-coated poly(lactic-co-glycolic acid) nanoparticles | en_US |
dc.type | Article | en_US |
dc.relation.volume | 78 | - |
dc.identifier.doi | 10.1016/j.biopha.2016.01.027 | - |
dc.relation.page | 226-233 | - |
dc.relation.journal | BIOMEDICINE & PHARMACOTHERAPY | - |
dc.contributor.googleauthor | Lee, Changkyu | - |
dc.contributor.googleauthor | Seo, Jisoo | - |
dc.contributor.googleauthor | Hwang, Ha Shin | - |
dc.contributor.googleauthor | Thao, Le Quang | - |
dc.contributor.googleauthor | Lee, Seunghyun | - |
dc.contributor.googleauthor | Lee, Eun Seong | - |
dc.contributor.googleauthor | Lee, Eun Hee | - |
dc.contributor.googleauthor | Choi, Han-Gon | - |
dc.contributor.googleauthor | Youn, Yu Seok | - |
dc.relation.code | 2016000352 | - |
dc.sector.campus | E | - |
dc.sector.daehak | COLLEGE OF PHARMACY[E] | - |
dc.sector.department | DEPARTMENT OF PHARMACY | - |
dc.identifier.pid | hangon | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.